All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Vaxxas Pty. Ltd. raised AU$34 million (US$23 million) to advance its needle-free COVID-19 vaccine program, which began in early November, and readouts from the study are expected in late February or early March, Vaxxas CEO David Hoey told BioWorld. The COVID-19 vaccine patch is based on the company’s high-density microarray patch technology that delivers Hexapro, a second-generation version of the spike protein used in all major U.S.-approved COVID-19 vaccines.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Akero, Bioxytran, Bloomsbury Genetic, Brim, Cerecin, Emmaus, In8bio, Liscure, Moderna, Molecular Targeting, Numinus, Quralis, Takeda, VBI, Visiox, Y-mabs.
CSPC Pharmaceutical Group Ltd. has obtained clearance from China's National Medical Products Administration (NMPA) to conduct clinical trials in China with SYH-2055, an oral small-molecule 3C-like protease (3CLpro) inhibitor against SARS-CoV-2.
New research has identified a novel receptor that interacts with the angiotensin-converting enzyme 2 (ACE2) by which the SARS-CoV-2 enters host cells, and shown it can be inhibited with marketed drugs, reducing expression of ACE2 and blocking viral entry.
China recently approved four COVID-19 vaccines for emergency use in a span of two days. The nods were granted to Clover Biopharmaceuticals Ltd., Sinocelltech Group Ltd., Beijing Wantai Biological Pharmacy Enterprise Co. Ltd. and Westvac Biopharma Co. Ltd. There is still no mRNA vaccine approved in the country.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Amarin, Ascletis, Delta-Fly, Moleculin, Novavax, Oncopeptides, Qualigen, Sionna.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Abiogen, Actinium, Altamedics, Addex, Daiichi Sankyo, Entrada, Gilead, Indivior, Instil, Kite, Revolution, Sanofi, Sensei, Sosei, Spikimm, Tevogen and Vertex.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Abbvie, Altavant, Clear Creek, Enzyvant, Equillium, Essential, Everson, Explorna, Hotspot, Intrinsic, Kyowa, MEI, Metrion, Nykode, Omnispirant, Ono, Pfizer, Replimune, Roche, Tris.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Alzheon, Biovie, Cassava, Celldex, Dragonfly, Editas, Gossamer, Imaginab, Kinarus, Leo, Medicinova, Mirati.
RSS
